Browse All
Displaying 1 - 2 of 2
Author:Boer, Ibolya Cree, Bruce Wiendl, Heinz Cross, Anne Delgado, Sylvia Habek, Mario Khachanova, Natalia Ward, Brian Totolyan, Natalia Mancione, Linda Sullivan, Roseanne Zielman, Ronald Hu, Xixi Das Gupta, Ayan Montalban, Xavier Winthrop, Kevin
Session Name:P1: Multiple Sclerosis: Clinical Practice and Decision Making 1
Topic:Multiple Sclerosis
Program Number:P1.010
Author Institution:Novartis Pharma AG, Basel, Switzerland UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA Department of Neurology with Institute of Translational Neurology, University of Münster, Muenster, Germany Washington University School of Medicine, Saint Louis, MO University of Miami Miller School of Medicine, Miami, FL University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia Pirogov Russian National Research Medical University, Moscow, Russian Federation Infectious Diseases Division, Research Institute of the McGill University Health Centre, Montreal, QC, Canada First Saint Petersburg State Medical University, St Petersburg , Russian Federation Novartis Pharmaceuticals Corporation, East Hanover, NJ Novartis Pharma B.V, Amsterdam, Netherlands Novartis Healthcare Private Limited, Hyderabad, India Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain School of Public Health at Oregon Health & Science University, Portland, OR
Author:Kieseier, Bernd Montalban, Xavier Williams, Mitzi Airas, Laura Saini, Sarbjit Hide, Michihiro Sussman, Gordon Nakahara, Jin Bermel, Robert Doerner, Thomas Loop, Brett DeLasHeras, Virginia Willi, Roman Haemmerle, Sibylle Zharkov, Artem Barbier, Nathalie Azmon, Amin Siegel, Richard Cenni, Bruno Wiendl, Heinz Maurer, Marcus Gimenez-Arnau, Ana Chitnis, Tanuja
Session Name:P8: Multiple Sclerosis: Non-MS CNS Neuroinflammatory Diseases and Progressive MS and Remyelination/Neuroprotection
Program Number:P8.015
Author Institution:Novartis Pharma AG, Basel, Switzerland Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain Joi Life Wellness Group, Atlanta, GA Turku University Hospital and University of Turku, Turku, Finland Johns Hopkins Asthma and Allergy Center, Baltimore, MD Hiroshima Citizens Hospital, Minami-ku, Japan University of Toronto, Toronto, ON, Canada Department of Neurology, Keio University School of Medicine, Tokyo, Japan Mellen Center for MS, Cleveland Clinic, Cleveland, OH Department of Rheumatology and Clinical Immunology, Charite – Universitätsmedizin Berlin, Berlin, Germany Novartis Pharmaceutical Corporation, Cambridge, MA Novartis Institutes for Biomedical Research, Basel, Switzerland Department of Neurology with Institute of Translational Neurology, University of Münster, Muenster, Germany Urticaria Center of Reference and Excellence, Institute of Allergology, Charité – Universitätsmedizin Berlin, Berlin, Germany Department of Dermatology, Hospital del Mar – IMIM, Universitat Pompeu Fabra, Barcelona, Spain Department of Neurology, Brigham and Women's Hospital, Boston, MA
